

1 Anti-SARS-CoV-2 antibody levels are concordant across multiple platforms but are not fully
2 predictive of sterilizing immunity
3
4 Benjamin T. Bradley¹, Andrew Bryan¹, Susan L. Fink¹, Erin A. Goecker¹, Pavitra Roychoudhury¹,
5 Meei-Li Huang¹, Haiying Zhu¹, Anu Chaudhary¹, Bhanupriya Madarampalli¹, Joyce Y.C. Lu¹, Kathy
6 Strand², Estella Whimbey², Chloe Bryson-Cahn², Adrienne Schippers², Nandita S. Mani², Gregory
7 Pepper¹, Keith R. Jerome^{1,3}, Chihiro Morishima¹, Robert W. Coombs^{1,2}, Mark Wener¹, Seth
8 Cohen², Alexander L. Greninger^{1,3} #

9
10 ¹ Department of Laboratory Medicine and Pathology, University of Washington Medical Center,
11 Seattle, WA

12 ² Division of Infectious Diseases, Department of Medicine, University of Washington Medical
13 Center, Seattle, WA

14 ³ Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA

15
16 #Corresponding author

17 Alexander L. Greninger, agrening@uw.edu

18 1616 Eastlake Ave E, Suite 320, Seattle, WA 98102

19 Phone: 415 439 3448, Fax: 206 616 4340

20 Running Title: anti-S assays

21 Keywords: Abbott Architect, SARS-CoV-2, spike protein, spike IgG, serology, COVID-19,

22 coronavirus

23 **Abstract**

24 With the availability of widespread SARS-CoV-2 vaccination, high-throughput quantitative anti-
25 spike serological testing will likely become increasingly important. Here, we investigated the
26 performance characteristics of the recently FDA authorized semi-quantitative anti-spike
27 AdviseDx SARS-CoV-2 IgG II assay compared to the FDA authorized anti-nucleocapsid Abbott
28 Architect SARS-CoV-2 IgG, Roche elecsys Anti-SARS-CoV-2-S, EuroImmun Anti-SARS-CoV-2
29 ELISA, and GenScript surrogate virus neutralization assays and examined the humoral response
30 associated with vaccination, natural protection, and breakthrough infection. The AdviseDx
31 assay had a clinical sensitivity at 14 days post-symptom onset or 10 days post PCR detection of
32 95.6% (65/68, 95% CI: 87.8-98.8%) with two discrepant individuals seroconverting shortly
33 thereafter. The AdviseDx assay demonstrated 100% positive percent agreement with the four
34 other assays examined using the same symptom onset or PCR detection cutoffs. Using a
35 recently available WHO International Standard for anti-SARS-CoV-2 antibody, we provide assay
36 unit conversion factors to international units for each of the assays examined. We performed a
37 longitudinal survey of healthy vaccinated individuals, finding median AdviseDx immunoglobulin
38 levels peaked seven weeks post-first vaccine dose at approximately 4,000 IU/mL. Intriguingly,
39 among the five assays examined, there was no significant difference in antigen binding level or
40 neutralizing activity between two seropositive patients protected against SARS-CoV-2 infection
41 in a previously described fishing vessel outbreak and five healthcare workers who experienced
42 vaccine breakthrough of SARS-CoV-2 infection – all with variants of concern. These findings
43 suggest that protection against SARS-CoV-2 infection cannot currently be predicted exclusively

- 44 using *in vitro* antibody assays against wildtype SARS-CoV-2 spike. Further work is required to
- 45 establish protective correlates of protection for SARS-CoV-2 infection.

46 **Introduction**

47 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) the etiologic agent of
48 coronavirus disease 19 (COVID-19) is responsible for an ongoing global pandemic. In addition to
49 infection control measures such as social distancing and masking, controlling the spread of the
50 outbreak will require a global vaccination campaign. Currently, three vaccines have received
51 FDA emergency use authorization with other candidates in late-phase clinical trials (1).
52 Common to all vaccine candidates is the inclusion of the receptor binding domain (RBD) or full-
53 length spike (S) of SARS-CoV-2 (2).

54
55 For SARS-CoV-2 and related coronaviruses, antibodies to the RBD of the spike protein have
56 demonstrated potent neutralizing activity at nanomolar concentrations (3, 4). In a recent meta-
57 analysis of individuals with naturally-acquired SARS-CoV-2 infection, neutralizing antibodies
58 were first detectable between seven to 15 days following symptom onset (5). Despite questions
59 regarding the durability of the antibody response and documented cases of reinfection,
60 longitudinal analysis of IgG levels and neutralizing potency suggest immunity persists in most
61 individuals for as long a time period as has been examinable to date (6, 7). However, some
62 individuals, including those who are older or immunosuppressed, may be at risk for a
63 suboptimal response to vaccination (8, 9).

64
65 The presence of neutralizing antibodies due to prior infection or vaccination has been shown to
66 be a correlate of protection against SARS-CoV-2 infection (10–12). Although Phase III vaccine
67 trials demonstrated excellent efficacies among treated populations (13, 14), a number of

68 subpopulations including pregnant women and immunocompromised individuals were
69 excluded from these trials. Moreover, uncertainty exists over the durability of protection after
70 vaccination (15). High-throughput, widely available laboratory measurements of protective
71 correlates would be extremely helpful in these and other populations. The current gold-
72 standard test, known as the plaque reduction neutralization assay (PRNA), is resource intensive
73 and requires BSL-3 conditions for testing. Currently, one surrogate neutralization assay has
74 received EUA-approval for clinical use. While this assay can be performed in BSL-2 laboratories
75 and has shown excellent correlation to PRNAs, it also suffers from similar limitations of
76 throughput and cost (16). The most widely used clinical platforms for monitoring immunity to
77 vaccine-preventable diseases including hepatitis B virus, measles virus, and varicella-zoster
78 virus are high-throughput, low-cost immunoassay analyzers, including the Roche cobas, Abbott
79 Architect, and Diasorin XL platforms, among others. Recently, the Abbott AdviseDx SARS-CoV-2
80 IgG II assay received emergency use authorization by the FDA. This chemiluminescent
81 microparticle immunoassay (CIMA) for the Abbott Architect platform is designed for semi-
82 quantitative detection of IgG class antibodies to the RBD of the SARS-CoV-2 spike protein.

83
84 Our laboratory previously examined the clinical performance characteristics of the anti-N SARS-
85 CoV-2 IgG assay for the Abbott Architect and found it to have adequate performance for
86 determining prior SARS-CoV-2 infection in a hospitalized cohort (17). However, this assay is
87 qualitative and designed to detect antibodies to the nucleocapsid, precluding the ability to
88 monitor vaccine response. In this study we examine the performance of the AdviseDx SARS-
89 CoV-2 IgG II assay and correlate its performance to four other assays (Abbott Architect SARS-

90 CoV-2 anti-nucleocapsid IgG, Roche Elecsys Anti-SARS-CoV-2 S, EuroImmun Anti-SARS-CoV-2
91 ELISA IgG , and GenScript surrogate virus neutralization test). The WHO International Standard
92 was also run on each platform to evaluate analytical sensitivity using the manufacturer's
93 cutoffs.
94
95 Important questions remain as to what binding antibody levels may be considered protective
96 against SARS-CoV-2 infection. We explored this question using the following approach: First, we
97 calculated median immunoglobulin values following SARS-CoV-2 vaccination over 11 weeks in a
98 group of healthy volunteers. Second, we compared the antibody response between a pair of
99 seropositive patients who were protected from SARS-CoV-2 infection during a previously
100 described outbreak on a fishery vessel and a group of five fully vaccinated healthy individuals
101 who subsequently experienced breakthrough SARS-CoV-2 infection. This study not only
102 demonstrates the acceptable analytical clinical performance of the Abbott AdviseDx assay, but
103 also provides context for how these values may be interpreted in vaccinated individuals.

104

105 **Materials and Methods**

106 *Study population & Specimen collection*

107 A total of 128 residual plasma specimens from 91 patients with a history of PCR-confirmed
108 SARS-CoV-2 infection or anti-N IgG antibodies were included in this study (raw data in
109 Supplemental Dataset 1). Residual serum from 104 individuals collected between June and
110 August of 2019 for anti-HSV western blot analysis was used as the negative control. 155
111 samples from 27 vaccinated asymptomatic ambulatory adult health care workers were

112 collected to assess the longitudinal response (raw data available in Supplemental Dataset 2.
113 These individuals received either the mRNA-1273 or BNT162b2 vaccine. Samples were obtained
114 from two seropositive individuals who previously demonstrated protection against SARS-CoV-2
115 infection during a previously described fishery vessel outbreak (10). Five samples were obtained
116 from fully vaccinated healthcare workers with PCR-confirmed SARS-CoV-2 infection and mild
117 COVID-19 symptoms. Diagnostic SARS-CoV-2 PCR tests included a Washington state authorized
118 CDC-based laboratory developed assay or FDA authorized Roche cobas SARS-CoV-2, Abbott
119 Alinity m SARS-CoV-2, or Hologic Panther Fusion SARS-CoV-2 assays (18). SARS-CoV-2 Whole
120 genome sequencing was performed using the Swift Biosciences v2 or Illumina COVID-Seq
121 amplicon tiling assays (19). This study was approved by the University of Washington
122 Institutional Review Board.

123

124 *Anti-N Abbott Architect SARS-CoV-2 IgG and Anti-S AdviseDx SARS-CoV-2 IgG II assays*

125 The emergency use authorized anti-N Architect SARS-CoV-2 IgG and anti-S AdviseDx SARS-CoV-
126 2 IgG II assays (Abbott, Chicago, IL) are chemiluminescent microparticle immunoassay (CIMA)
127 designed to measure IgG antibodies binding the N protein and S protein, respectively, and were
128 performed on an Architect i2000SR. Results from the anti-N SARS-CoV-2 IgG assay are reported
129 as index values. The index value of 1.40 or greater was classified as positive per manufacturer's
130 recommendation for the anti-N Abbott Architect SARS-CoV-2 IgG assay. Results from the
131 anti-S AdviseDx SARS-CoV-2 IgG II assay are reported as arbitrary units per milliliter (AU/mL).
132 The manufacturer's suggested positive cutoff of 50 AU/mL was used. Inter-day and inter-assay
133 studies were performed over three days by two different operators.

134

135 *Roche Elecsys Anti-SARS-CoV-2 S*

136 The Elecsys Anti-SARS-CoV-2 S assay (Roche Diagnostics International Ltd, Rotkreuz,
137 Switzerland) is an electrochemiluminescence immunoassay which uses a double-antigen
138 sandwich design for the detection of immunoglobulins (predominantly IgG, but also IgA and
139 IgM) to the RBD domain of the S protein. Samples were prepared according to the
140 manufacturer's instructions and analyzed on the Roche cobas e 411 platform. Using the
141 manufacturer's guidelines, sample values ≥ 0.8 AU/mL were classified as positive for anti-SARS-
142 CoV-2 antibodies. No dilutions were performed on specimens to extend the measurement
143 range of the assay which does not report values above 250 AU/mL.

144

145 *EuroImmune Anti-SARS-CoV-2 ELISA*

146 The EuroImmune anti-SARS-CoV-2 IgG assay is a semi-quantitative ELISA detecting antibodies
147 which bind the S1 subunit of the spike protein. Samples are loaded into reagent wells coated
148 with the spike protein, washed, and then incubated with enzyme-conjugated anti-human IgG
149 generating a colorimetric signal. Results are provided as a semi-quantitative measurement of
150 the signal of the experimental sample divided by the signal of the calibrator (OD ratio). Per the
151 manufacturer's insert values < 0.8 are considered negative, ≥ 0.8 to < 1.0 borderline, and ≥ 1.1
152 positive. For this study we classified borderline results as positive.

153

154 *GenScript Surrogate Virus Neutralization Test*

155 The GenScript Surrogate Virus Neutralization Test (Piscataway, NJ, USA) assay was performed
156 according to the manufacturer's instructions. The test examines the ability of sera to block
157 binding of SARS-CoV-2 spike RBD to the human ACE2 receptor. Absorbance was read at 450 nm
158 on a VICTOR Nivo (PerkinElmer, Waltham, MA, USA) reader. Values are reported as percent
159 neutralization relative to a negative control sample provided by the manufacturer. Samples
160 demonstrating $\geq 30\%$ inhibition of ACE2 binding were classified as positive as recommended by
161 the manufacturer.

162

163 *SARS-CoV-2 Spike Pseudotyped Lentivirus Neutralization assay*

164 1.25×10^4 293T-ACE2 cells were seeded in 96-well plates and incubated in DMEM + 10% FBS for 16-
165 18 hrs. The following day, 1.0×10^7 RLU/well SARS-CoV-2 D614G Spike pseudotyped lentivirus was
166 diluted 1:10 in DMEM with 10% FBS complete media (20). Sera was diluted 1:20 in DMEM with
167 10% FBS and seven three-fold serial dilutions were prepared. Equal parts diluted sera and
168 pseudovirus were combined and incubated for one hour at 37°C. The mixture was added to the
169 cells and incubated for fifty-two hours at 37°C. Following incubation, the media was removed
170 and 30 μ l of luciferase substrate (Promega, Madison, WI, USA) was added. After two minutes of
171 incubation, luminescence was measured on the VICTOR Nivo and IC50 was calculated from a
172 standard curve using the CV30 monoclonal antibody (Absolute Antibody, Oxford, UK).

173

174 *Preparation of the International Standard*

175 The WHO First International Standard for SARS-CoV-2 antibody were prepared according to the
176 manufacturer's instructions (21). The lyophilized sample was provided at 250IU/ampoule and

177 resuspended in 250µl of deionized water to create a 1000 IU/mL stock solution. The stock was
178 diluted 1:10 to prepare a working solution with sufficient volume for analysis across the various
179 platforms.

180

181 *Statistical Analysis*

182 Correlation studies were performed using Spearman's coefficient. Assay performance, linear
183 regression, curve fitting calculations were performed using Prism 9 (GraphPad Software, LLC,
184 San Diego, CA, USA).

185

186 **Results**

187 *The AdviseDx SARS-CoV-2 IgG II assay is 95.6% sensitive and 100% specific in individuals at least*
188 *14 days post-symptom onset or 10 days post-first positive PCR result*

189 To assess the sensitivity and specificity of the AdviseDx SARS-CoV-2 IgG II assay, a total of 172
190 patient samples (68 positive, 104 negative) were tested. Positive cases were classified as
191 individuals with a PCR-confirmed diagnosis of SARS-CoV-2 infection who were at least 14 days
192 post-symptom onset or 10 days post-first positive PCR result. Negative sera were collected
193 during July and August 2019, prior to when SARS-CoV-2 was thought to be circulating in the
194 western Washington area (22). Using these criteria, the assay had a sensitivity of 95.6% (65/68
195 samples; 95% CI: 87.8-98.8%) (Figure 1A, Supplemental Table 1). Importantly, two of the three
196 cases that initially tested negative were in clinically asymptomatic individuals detected by pre-
197 admission SARS-CoV-2 PCR screening. Based on the manufacturer's recommended cutoff of 50
198 AU/mL, these two individuals tested antibody negative on days 11 (13.8 AU/mL) and 13 (10.9

199 AU/mL) and seroconverted on days 13 (77.3 AU/mL) and 18 (168.3 AU/mL) post-PCR,
200 respectively. The third individual was borderline anti-S seronegative (19.5 AU/mL) at day 15
201 post-symptom onset and died due to COVID-19 pneumonia on day 17 post-symptom onset.
202 Specificity was calculated to be 100% (104/104 samples; 95% CI 96.4-100%) (Table 1B). The
203 median AU/mL of these specimens was 1.8 AU/mL (range 0 – 32.9 AU/mL), and the limit of
204 blank, calculated as the mean of negative samples + 3 S.D., was 17.3 AU/mL, well below the
205 manufacturer’s recommended cutoff of 50 AU/mL.

206
207 *The AdviseDx SARS-CoV-2 IgG II assay is linear over the analytic measurement interval with a*
208 *coefficient of variation <5% near the positive cutoff*

209 Per the manufacturer’s insert the AdviseDx SARS-CoV-2 IgG II has a limit of quantitation of 22.0
210 AU/mL and an upper limit of quantitation of 25,000 AU/mL. To assess the linearity of the assay,
211 we performed 1:2 serial dilutions of a high-positive sample from 37,256 AU/mL to ~12 AU/mL.
212 Each sample dilution was measured in triplicate. The AdviseDx level of the neat sera was
213 calculated from a 10x dilution. Results demonstrated excellent linearity beyond the
214 manufacturer’s analytical measurement interval ($R^2=0.9989$) (Supplemental Figure 1). To assess
215 for assay reproducibility, the coefficient of variation (CV) was measured in four samples near
216 the manufacturer’s suggested positive cutoff over four days. The assay demonstrated a CV less
217 than 5% at all dilutions above the positive threshold (550, 140, and 70 AU/mL) during intraday
218 and interday measurements. For the sample below the positive threshold (40 AU/mL) the CV
219 was 5% and 7.7% on intraday and interday measurements, respectively (Supplemental Table 2).

220

221 *The AdviseDx SARS-CoV-2 IgG II has 100% positive agreement with three other EUA*
222 *immunoassays*

223 Results of the AdviseDx assay were compared to three serologic binding assays with prior EUAs,
224 Abbott Architect SARS-CoV-2 IgG (nucleocapsid), EuroImmun Anti-SARS-CoV-2 ELISA (spike S1
225 subunit), and Roche Elecsys Anti-SARS-CoV-2 S (spike RBD). Using a cutoff of 14 days post-
226 symptom onset or 10 days post first positive PCR result, the positive percent agreement (PPA)
227 of the AdviseDx with the three other assays was 100% (Table 1 A-C). When patient samples
228 were examined regardless of collection time, the AdviseDx PPA agreement for the Abbott
229 Architect, EuroImmun, and Roche assays were 98.3% (114/116), 100% (95/95), and 100%
230 (102/102) respectively (Supplemental Table 3).

231 A total of 13 samples with at least one qualitative test result discrepancy were
232 observed, which were mostly driven by negative results on the EuroImmun test (Supplemental
233 Table 4). Discrepant cases occurred near the time of seroconversion in patients with available
234 clinical data. Of the discrepant cases, two were considered to be early positives by the Abbott
235 Architect anti-N assay based on negative results on the other three platforms. Both of these
236 cases had Abbott Architect anti-N index values close the cutoff at 1.53 and 1.44. Of the
237 remaining cases, 11/11 were AdviseDx positive, 10/11 Abbott Architect anti-N positive, 8/11
238 Roche positive, and 0/11 EuroImmun positive. Quantitative results of the AdviseDx assay were
239 highly correlated to the three other platforms as measured by Spearman's coefficient: Abbott
240 Architect anti-N ($r=0.89$), EuroImmun anti-S1 ($r=0.95$), Roche anti-RBD ($r=0.90$), $p<0.001$ for all
241 comparisons. Linear regression and goodness of fit were calculated following log-
242 transformation of AdviseDx values. The goodness of fit (R^2) of the log-transformed AdviseDx

243 values to the quantitative results of the Abbott Architect anti-N, EuroImmun anti-S1, and Roche
244 anti-S/RBD assays were 0.42, 0.84, and 0.73, respectively (Figure 2 A-C), which was chiefly
245 affected by the limited reportable range of these assays. Categorical agreement and
246 assessment of linearity between the Abbott Architect anti-N, EuroImmun, Roche, and GenScript
247 assays are available in Supplemental Figure 2 and Supplemental Table 5.

248

249 *The AdviseDx SARS-CoV-2 IgG II assay demonstrates 100% positive agreement with FDA-*
250 *emergency use authorized surrogate virus neutralization test*

251 As the GenScript Surrogate Virus Neutralization Test is the only currently available
252 neutralization-based assay that has been authorized by the FDA, we compared its results to the
253 AdviseDx SARS-CoV-2 IgG II results. Categorical evaluation demonstrated a positive percent
254 agreement of 100% (89/89 samples; 95% CI: 95.9-100%) in patients with a documented history
255 of SARS-CoV-2 infection (Table 1D). AdviseDx values positively correlated with increasing
256 percent neutralization by Spearman's analysis ($r=0.86$, $p<0.001$). Following log-transformation
257 of the AdviseDx values, a linear regression model was fit to the data (Figure 2D). Neutralization
258 values of 30% (positive cutoff), 50%, and 80% on the GenScript assay corresponded to 107, 369,
259 and 2340 AU/mL on the Abbott IgG II assay, respectively. Similarly, a 18% neutralization value
260 correlated to 50 AU/mL, the positive cutoff, for the AdviseDx assay.

261

262 *Increases in anti-S binding antibodies and neutralization activity are observed in individuals*
263 *following SARS-CoV-2 infection and vaccination*

264 The kinetics of the Genscript and AdviseDx assays were measured over 10-15 days in four
265 patients hospitalized for COVID-19 and over 44-59 days in four individuals who received mRNA
266 vaccines to SARS-CoV-2. Both anti-S immunoglobulins and neutralization values increased over
267 time with high neutralizing levels achieved in all patients (Figure 3). Patients 1 and 2 had
268 positive AdviseDx results on days 8-9, with a positive GenScript 1-2 days later. Patient 4 tested
269 positive by both assays ten days post-symptom onset. For Patient 3, clinical samples were
270 available starting on day 5 post-symptom onset, and both were found to be positive at that
271 time. In the vaccinated patients, a decrease in AdviseDx values was observed at later timepoints
272 although the surrogate neutralizing results remained elevated.

273

274 *Implementation of the International Standard demonstrates variable sensitivity among*
275 *serologic assays for SARS-CoV-2 using the manufacturer's recommended cutoffs*

276 To determine the positivity threshold for each assay in standardized International Units, a
277 dilution series of the WHO International Standard for SARS-CoV-2 Antibody was prepared and
278 run in triplicate on all platforms (Table 2). For those assays with demonstrated acceptable
279 linearity across the analytic measurement range (AdviseDx, EuroImmuno, Roche, Abbott
280 Architect anti-N) the positive cutoff in IU/mL was calculated by linear regression. In increasing
281 order, the manufacturers' recommended assay cutoffs were determined to be: Roche (3.2
282 IU/mL), AdviseDx (8.4 IU/mL), EuroImmuno (30.2 IU/mL), GenScript (10-50 IU/mL), and Abbott
283 Architect anti-N (56.2 IU/mL). All assays demonstrated an acceptable coefficient of variation
284 (less than 20%) at values near their positive cutoffs.

285

286 *Longitudinal measurement of anti-SARS-CoV-2 immunoglobulins following vaccination*

287 To understand how anti-S levels change in healthy individuals during vaccination, we examined
288 a total of 155 weekly samples obtained from 27 volunteers (age range 20-72) over up to 11
289 weeks post-vaccination with either the mRNA-1273 or BNT162b2 SARS-CoV-2 vaccines. Sera
290 were analyzed by the AdviseDx, EuroImmun, and Roche anti-S assays and median values along
291 with the 10th-90th percentiles were calculated for the assay results (Table 3). Sera were
292 universally positive by all assays by week 3 after the first vaccine dose. Median AdviseDx anti-
293 spike IgG levels increased more than 100-fold more than two weeks after the first dose and
294 more than 10-fold after administration of the second dose and peaked at seven weeks after
295 first vaccine dose at 23,881 AU/mL (7,304 to >25,000 AU/mL, 10th-90th percentiles). All sera
296 obtained more than six weeks after vaccination exceeded the analytical reportable range of the
297 anti-S Roche assay at >250 AU/mL.

298

299

300 *SARS-CoV-2 anti-S immunoglobulin levels and neutralization results do not significantly differ*
301 *between individuals protected after exposure and vaccine breakthrough cases*

302 Prior to the widespread emergence of SARS-CoV-2 variants, we previously described an
303 outbreak of SARS-CoV-2 aboard a fishing vessel in which three individuals with pre-existing
304 SARS-CoV-2 antibodies demonstrated immunity to re-infection (10). These individuals most
305 closely represent the results of a human infection challenge model where an individual with
306 known immunity experiences multiple known exposures to a pathogen. Residual samples were
307 available for two of these individuals with AdviseDx values of 5,303 AU/mL and 1,240 AU/mL.

308 These samples were also tested using across the other available platforms in our study;
309 however, the sample for Patient 2 was exhausted during this process. For the three assays
310 which demonstrated linearity across the analytical range (AdviseDx, EuroImmun, and Roche),
311 the international units per milliliter (IU/mL) were calculated by linear regression. Antibody
312 levels and neutralizing activity were well above the positive cutoff as measured on all
313 platforms, including anti-N (Abbott Architect) and anti-S (AdviseDx, EuroImmun, Roche)
314 antibody responses. When results were standardized to international units, for the three assays
315 which demonstrated linearity across the analytical range (AdviseDx, EuroImmun, and Roche),
316 protection could be observed at levels as low as 81 IU/mL (Table 4).

317
318 A second group of samples were collected from five healthcare workers who experienced mild
319 SARS-CoV-2 infection after more than four weeks following their second vaccine dose. All
320 individuals endorsed some form of upper respiratory symptoms after receiving the BNT162b2
321 vaccine and had surprisingly strong viral loads with an average Ct of 18.4 (range 16.0-20.8,
322 Supplemental Table 6). Serum specimens were collected 1-4 days following symptom onset,
323 tested across all platforms, and standardized to IU/mL when applicable (Table 4). Consistent
324 with a history of prior vaccination and early infection, detectable anti-S and undetectable anti-N
325 antibody responses were observed. In four of five patients, antibody levels and surrogate
326 neutralization results were equal to or greater than samples from the fishing vessel cohort. One
327 patient (HCW_02) demonstrated low positive surrogate neutralization (35.6%, positive cutoff:
328 30%) and low AdviseDx values compared to the other members of the cohort. However, this
329 patient's anti-S antibody binding activity as measured on the EuroImmun and Roche platforms

330 were greater than at least one of the protective fishing vessel samples. Whole genome
331 sequencing of the healthcare worker isolates identified the CAL.20C variant of concern (4
332 isolates 20C/B.1.429, 1 isolate 20C/B.1.427). Patient demographics, symptoms, time to first
333 positive PCR result, Ct value, and time to draw for serology for the healthcare worker cohort
334 are provided in Supplementary Table 6.

335

336 **Discussion**

337 Widespread vaccination campaigns are currently underway, and present an opportunity to
338 elucidate correlates of protection from SARS-CoV-2 infection. While many methodologies exist
339 to assess and monitor humoral immunity, the most tractable for clinical laboratory workflows
340 are enzyme immunoassays which can be run at high-throughput with relatively low cost. In this
341 manuscript, we examined the performance characteristics of four EIAs, including the AdviseDx
342 SARS-CoV-2 IgG II assay which was recently granted EUA status, and one surrogate
343 neutralization assay. We found nearly 100% categorical agreement in most comparisons and
344 good correlation between quantitative values, particularly for the anti-S assays. Additionally,
345 we explored how these assays may be used in assessing immune response by examining a
346 cohort of vaccinated healthcare workers who demonstrated vaccine-breakthrough SARS-CoV-2
347 infection and individuals who demonstrated clinical resistance to infection.

348

349 We found the AdviseDx SARS-CoV-2 IgG II assay to have acceptable performance characteristics
350 and strong agreement with four other serologic tests previously granted emergency use
351 authorization. Among a set of 172 patient samples (68 positive, 104 negative), the AdviseDx

352 assay demonstrated a 95.6% sensitivity and 100% specificity. Compared to the manufacturer's
353 reported sensitivity and specificity of 98.11% and 99.55%, the clinical sensitivity calculated in
354 our study may have been lower due to strict case definitions for infected individuals (14 days
355 post-symptom onset or 10 days following first positive SARS-CoV-2 PCR result) and the inclusion
356 of acutely ill patients (23, 24). Of the three COVID-19 patients who tested negative using this
357 cutoff for the AdviseDx assay, two seroconverted over the following eight days and one died to
358 COVID-19 pneumonia. At concentrations above the manufacturer's set positive threshold of 50
359 AU/mL the assay had an acceptable coefficient of variation of less than 5%. While the CV
360 slightly increased at values below the positive threshold, the limit of the blank was calculated to
361 be 17.3 AU/mL, suggesting that negative samples are rarely near the positive threshold and
362 unlikely to cause a false positive result due to analytic variation. In contrast to the Abbott
363 Architect anti-N assay which has demonstrated poor linearity at index values above 3, the
364 AdviseDx demonstrated excellent linearity even when values outside the manufacturer's
365 analytical measurement range were tested ($R^2=0.998$) (25).

366
367 The AdviseDx assay demonstrated similar performance to three EUA serological binding assays
368 (Abbott Architect SARS-CoV-2 IgG, EuroImmune Anti-SARS-CoV-2 ELISA, and Roche Elecsys anti-
369 SARS-CoV-2 S) measuring SARS-CoV-2 immunoglobulins. For samples collected from patients
370 more than 14 days post symptom onset or 10 days after initial positive PCR result, the AdviseDx
371 demonstrated a 100% positive predictive agreement with all three assays. This high percentage
372 of agreement is in keeping with data from other high-throughput platforms as well (26). A total
373 of 13 discordant samples were identified when categorical agreement across all platforms was

374 assessed regardless of specimen collection date. In two situations, one of the four assays
375 reported a positive value. This occurred twice for the Abbott Architect anti-N assay which
376 reported values near the positive cutoff. Among the other 11 cases, all were AdviseDx positive.
377 Agreement of the other assays with the AdviseDx was as follows: Abbott Architect anti-N
378 (10/11), Roche (8/11), EuroImmun (0/11). Interestingly, the EuroImmun assay, despite having
379 the most instances of discordance, was analytically more sensitive compared to the Abbott
380 Architect anti-N assay when measuring the International Standard (30.2 IU/mL v. 56.2 IU/mL).
381 The discrepancy may reflect a higher relative presence of anti-S antibodies as compared to anti-
382 N immunoglobulins in the international standard. However, other studies have suggested the
383 EuroImmun assay may be more sensitive than the Abbott Architect anti-N (27, 28). It also worth
384 noting that assay sensitivity is heavily dependent on the non-standardized placement of a given
385 manufacturer's chosen cutoff (29, 30).

386
387 The gold standard PRNA method for determining protective antibody titers is time-consuming
388 and requires access to BSL-3 facilities if live SARS-CoV-2 is used (31). While alternative PRNAs
389 using pseudoviruses exist, variation in titer measurements has been demonstrated for different
390 vectors and cell lines (32). As we were unable to compare the results of the AdviseDx SARS-
391 CoV-2 IgG II assay to a gold-standard PRNA or pseudovirus neutralization assay in this study, we
392 instead compared the AdviseDx to a surrogate virus neutralization assay. This assay is currently
393 the only SARS-CoV-2 neutralization assay with EUA approval and has demonstrated excellent
394 correlation with the gold-standard PRNAs (16). Our results demonstrated a positive correlation
395 between anti-S IgG levels and neutralizing values ($R=0.86$, $p<0.001$). When regression analysis

396 was performed, we calculated that the 30% neutralizing level (positive cutoff) of the GenScript
397 assay corresponded to value of 107 AU/mL on the AdviseDx assay. This exceeds the
398 manufacturer's recommended positivity threshold of 50 AU/mL and suggests that when
399 samples are discrepant, they are likely to be AdviseDx positive/ GenScript negative. We
400 observed this trend in our data set with a total of 9 AdviseDx positive/ GenScript negative and 0
401 AdviseDx negative/ GenScript positive discrepancies. Five of these discrepant GenScript
402 negative results fell between 20%-30% inhibition, and arose from the modification made by
403 GenScript in their positive cutoff from 20% inhibition (in RUO documents) to 30% inhibition in
404 their EUA application (33). The AdviseDx values ranged from 50.1-290.7 AU/mL in discrepant
405 samples. Clinical histories were available in six of the nine discrepant cases. In two instances,
406 samples were collected from patients greater than 14 days after symptom onset. These results
407 suggest the GenScript assay is less clinically sensitive for detection of recent SARS-CoV-2
408 infection. While the functional data provided by the GenScript assay (i.e. inhibition of ACE2
409 binding) may better assess for protective antibodies, four of five patients with SARS-CoV-2
410 infection following vaccination were found to have inhibition levels >89%. These results
411 encourage the cautious interpretation surrogate inhibition assays as markers of sterilizing
412 immunity, especially in the context of emerging variants.

413

414 The WHO International Standard for SARS-CoV-2 antibodies was approved in December 2020
415 and each vial contains 250 IU of the standard (21). We created a dilution series ranging from
416 100-1 IU/mL and assessed results over five different SARS-CoV-2 platforms. Using the
417 manufacturer's recommended cutoff values, the Roche was most sensitive at 3.2 IU/mL. The

418 AdviseDx assay had the second lowest threshold for positive detection (8.4 IU/mL) with a 4.6%
419 coefficient of variation. The least sensitive test was the Abbott Architect anti-N (56.2 IU/mL).
420 The IS is prepared at a stock concentration of 1000 IU/mL, however, due to the need to test
421 replicates over a range of instruments, testing was started at 100 IU/mL. This prevented
422 standardization of higher values from assays which were non-linear (i.e. the Abbott Architect
423 anti-N and GenScript).

424
425 Patients with innate or acquired immunosuppressive conditions have demonstrated
426 poor antibody responses following vaccination to other viral pathogens (8, 9). Similar trends are
427 being documented following SARS-CoV-2 vaccination (34). Given the severe impact COVID-19
428 can have on these individuals, longitudinal monitoring of antibody levels may impact decisions
429 related to administering booster vaccinations and altering immunosuppressive regimens. We
430 gathered a small-scale data set of 155 samples from 27 healthcare workers who were
431 vaccinated with mRNA-1273 or BNT162b2 to help characterize what may be considered a
432 typical antibody response. The first positive results were detected on all platforms by three
433 weeks after the first vaccine dose. Antibody levels significantly increased and peaked at 7
434 weeks, corresponding to the anamnestic booster response. These values may be helpful to
435 physicians as they seek to determine if their patients have demonstrated an appropriate
436 antibody response. Certainly, more work is needed on longitudinal monitoring of antibody
437 levels from vaccination and their functional correlates.

438

439 Our study is limited by the relatively small number of patients sampled. While we examined
440 over 100 specimens to determine assay specificity, a larger number should be examined if the
441 AdviseDx assay were to be employed for use in serosurveys. However, test specificity for anti-S
442 serological tests may be less crucial if used to assess serostatus of vaccinated patients. The
443 samples used for determining test sensitivity were primarily obtained from patients who were
444 hospitalized with COVID-19. While seroconversion may begin as early as six days following
445 infection, three patients in our cohort were classified as seronegative when using a cutoff of 14
446 days post symptom onset or 10 days post first PCR positive in asymptomatic cases. Two of the
447 patients who failed to seroconvert within this timeframe were asymptomatic and eventually
448 seroconverted 13 and 18 days following their first positive SARS-CoV-2 PCR result, indicating
449 anti-S levels are likely associated with the degree of symptoms or infection (24). The third
450 patient who failed to seroconvert died from COVID-19 pneumonia at 17 days post-symptom
451 onset. Several published reports support the view that a cutoff of 14 days post-symptom onset
452 may be too conservative when calculating the sensitivity of SARS-CoV-2 serologic assay. In a
453 series of SARS-CoV-2 infected patients who did not require ICU admission, the 95% CI for
454 seroconversion extended to 25 days post symptom onset (24). Similarly, delayed antibody
455 response at the time of hospital admission for COVID-19 may be associated with poor outcomes
456 (35). These data suggest a longer duration from symptom onset may be appropriate when
457 assessing sensitivity in previously hospitalized or severely ill patients.

458

459 During the early phase of the pandemic, serologic assays were used to diagnose patients with
460 prior SARS-CoV-2 infection and to perform seroprevalence studies. However, with the

461 availability of FDA-authorized vaccines and more candidates entering late phase trials, the
462 ability to quantitatively measure the immune response to SARS-CoV-2 may be useful as a
463 biomarker for protection. Such an approach for would be similar to the current practice used in
464 hepatitis B serologic monitoring, where anti-HBs IgG levels above 10 mIU/mL are considered
465 protective (36). To accomplish this task for SARS-CoV-2, studies must be designed to assess the
466 protective threshold. We explored the question of what antibody levels may be considered
467 protective across various platforms through testing samples from three individuals with pre-
468 existing antibodies who demonstrated resistance to multiple SARS-CoV-2 challenges and five
469 individuals who experienced SARS-CoV-2 infection greater than four weeks after receiving their
470 second dose of the BNT162b2 vaccine. Interestingly, we found no difference in the antibody
471 levels between these two groups. It should be noted that the fishing vessel samples were
472 collected prior to the emergence of clinically significant variants. In the vaccine-breakthrough
473 group, all individuals were infected with the California variants 20.C B.1.427/B.1.429. This
474 variant was initially identified in January 2021 and retrospectively found to be in circulation
475 since May 2020 (37). Compared to the wild-type strain, the B.1.427/B.1.429 variants
476 demonstrate an L452R mutation in the RBD and may be associated with increased
477 transmissibility (38). When sera from vaccinated individuals was tested against the
478 B.1.427/B.1.429 variant, it demonstrated a 2 to 3-fold reduction in neutralization compared to
479 the wild type (38, 39). The emergence of novel variants highlights several challenges for
480 diagnostic assays including the difficulty in establishing protective thresholds and impact on the
481 design of capture antigens for EIAs. Though it is exceedingly difficult to profile strain-specific
482 immunity in the context of high-throughput FDA authorized assays given the rapid pace of viral

483 evolution, further work in this space is required to realize more perfect measurements of
484 immune protection.

485

486 **Acknowledgements:** The authors thank the staff of the University of Washington Medical
487 Center infection prevention team and virology and immunology clinical laboratories. ALG
488 reports contract testing from Abbott Laboratories and research support from Gilead and Merck,
489 outside of the described work. Abbott had no role in the design or execution of the study.

- 490 1. FDA COVID-19 Vaccines. <https://www.fda.gov/emergency-preparedness-and->
491 [response/coronavirus-disease-2019-covid-19/covid-19-vaccines](https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines). Accessed February 4th,
492 2021.
- 493 2. Krammer F. 2020. SARS-CoV-2 vaccines in development. 7830. *Nature* 586:516–527.
- 494 3. Robbiani DF, Gaebler C, Muecksch F, Lorenzi JCC, Wang Z, Cho A, Agudelo M, Barnes CO,
495 Gazumyan A, Finkin S, Hägglöf T, Oliveira TY, Viant C, Hurley A, Hoffmann H-H, Millard KG,
496 Kost RG, Cipolla M, Gordon K, Bianchini F, Chen ST, Ramos V, Patel R, Dizon J, Shimeliovich I,
497 Mendoza P, Hartweger H, Nogueira L, Pack M, Horowitz J, Schmidt F, Weisblum Y,
498 Michailidis E, Ashbrook AW, Waltari E, Pak JE, Huey-Tubman KE, Koranda N, Hoffman PR,
499 West AP, Rice CM, Hatzioannou T, Bjorkman PJ, Bieniasz PD, Caskey M, Nussenzweig MC.
500 2020. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. 7821.
501 *Nature* 584:437–442.
- 502 4. Jiang L, Wang N, Zuo T, Shi X, Poon K-MV, Wu Y, Gao F, Li D, Wang R, Guo J, Fu L, Yuen K-Y,
503 Zheng B-J, Wang X, Zhang L. 2014. Potent Neutralization of MERS-CoV by Human
504 Neutralizing Monoclonal Antibodies to the Viral Spike Glycoprotein. *Sci Transl Med*
505 6:234ra59-234ra59.
- 506 5. Post N, Eddy D, Huntley C, Schalkwyk MCI van, Shrotri M, Leeman D, Rigby S, Williams SV,
507 Bermingham WH, Kellam P, Maher J, Shields AM, Amirthalingam G, Peacock SJ, Ismail SA.
508 2020. Antibody response to SARS-CoV-2 infection in humans: A systematic review. *PLOS*
509 *ONE* 15:e0244126.

- 510 6. Tillett RL, Sevinsky JR, Hartley PD, Kerwin H, Crawford N, Gorzalski A, Laverdure C, Verma
511 SC, Rossetto CC, Jackson D, Farrell MJ, Hooser SV, Pandori M. 2021. Genomic evidence for
512 reinfection with SARS-CoV-2: a case study. *Lancet Infect Dis* 21:52–58.
- 513 7. Wajnberg A, Amanat F, Firpo A, Altman DR, Bailey MJ, Mansour M, McMahon M, Meade P,
514 Mendu DR, Muellers K, Stadlbauer D, Stone K, Strohmeier S, Simon V, Aberg J, Reich DL,
515 Krammer F, Cordon-Cardo C. 2020. Robust neutralizing antibodies to SARS-CoV-2 infection
516 persist for months. *Science* 370:1227–1230.
- 517 8. Jaffe D, Papadopoulos EB, Young JW, O’Reilly RJ, Prockop S, Kernan NA, Jakubowski A,
518 Boulad F, Perales M-A, Castro-Malaspina H, Small TN. 2006. Immunogenicity of
519 recombinant hepatitis B vaccine (rHBV) in recipients of unrelated or related allogeneic
520 hematopoietic cell (HC) transplants. *Blood* 108:2470–2475.
- 521 9. McElhaney JE. 2011. Influenza vaccine responses in older adults. *Ageing Res Rev* 10:379–
522 388.
- 523 10. Addetia A, Crawford KHD, Dingens A, Zhu H, Roychoudhury P, Huang M-L, Jerome KR,
524 Bloom JD, Greninger AL. 2020. Neutralizing Antibodies Correlate with Protection from SARS-
525 CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate. *J Clin Microbiol*
526 58.
- 527 11. Amit S, Regev-Yochay G, Afek A, Kreiss Y, Leshem E. 2021. Early rate reductions of SARS-
528 CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients. *The Lancet* 0.

- 529 12. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Roupael
530 N, Creech CB, McGettigan J, Khetan S, Segall N, Solis J, Brosz A, Fierro C, Schwartz H, Neuzil
531 K, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Mascola J, Polakowski L,
532 Ledgerwood J, Graham BS, Bennett H, Pajon R, Knightly C, Leav B, Deng W, Zhou H, Han S,
533 Ivarsson M, Miller J, Zaks T. 2021. Efficacy and Safety of the mRNA-1273 SARS-CoV-2
534 Vaccine. *N Engl J Med* 384:403–416.
- 535 13. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Roupael
536 N, Creech CB, McGettigan J, Khetan S, Segall N, Solis J, Brosz A, Fierro C, Schwartz H, Neuzil
537 K, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Mascola J, Polakowski L,
538 Ledgerwood J, Graham BS, Bennett H, Pajon R, Knightly C, Leav B, Deng W, Zhou H, Han S,
539 Ivarsson M, Miller J, Zaks T. 2021. Efficacy and Safety of the mRNA-1273 SARS-CoV-2
540 Vaccine. *N Engl J Med* 384:403–416.
- 541 14. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G,
542 Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV,
543 Cooper D, Frenck RW, Hammitt LL, Türeci Ö, Nell H, Schaefer A, Ünal S, Tresnan DB, Mather
544 S, Dormitzer PR, Şahin U, Jansen KU, Gruber WC. 2020. Safety and Efficacy of the BNT162b2
545 mRNA Covid-19 Vaccine. *N Engl J Med* 383:2603–2615.
- 546 15. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G,
547 Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV,
548 Cooper D, Frenck RW, Hammitt LL, Türeci Ö, Nell H, Schaefer A, Ünal S, Tresnan DB, Mather

- 549 S, Dormitzer PR, Şahin U, Jansen KU, Gruber WC. 2020. Safety and Efficacy of the BNT162b2
550 mRNA Covid-19 Vaccine. *N Engl J Med* 383:2603–2615.
- 551 16. Tan CW, Chia WN, Qin X, Liu P, Chen MI-C, Tiu C, Hu Z, Chen VC-W, Young BE, Sia WR, Tan Y-
552 J, Foo R, Yi Y, Lye DC, Anderson DE, Wang L-F. 2020. A SARS-CoV-2 surrogate virus
553 neutralization test based on antibody-mediated blockage of ACE2–spike protein–protein
554 interaction. *Nat Biotechnol* 38:1073–1078.
- 555 17. Bryan A, Pepper G, Wener MH, Fink SL, Morishima C, Chaudhary A, Jerome KR, Mathias PC,
556 Greninger AL. 2020. Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG
557 Assay and Seroprevalence in Boise, Idaho. *J Clin Microbiol* 58.
- 558 18. Lieberman JA, Pepper G, Naccache SN, Huang M-L, Jerome KR, Greninger AL. 2020.
559 Comparison of Commercially Available and Laboratory Developed Assays for in vitro
560 Detection of SARS-CoV-2 in Clinical Laboratories. *J Clin Microbiol*
561 <https://doi.org/10.1128/JCM.00821-20>.
- 562 19. Addetia A, Lin MJ, Peddu V, Roychoudhury P, Jerome KR, Greninger AL. 2020. Sensitive
563 Recovery of Complete SARS-CoV-2 Genomes from Clinical Samples by Use of Swift
564 Biosciences’ SARS-CoV-2 Multiplex Amplicon Sequencing Panel. *J Clin Microbiol* 59.
- 565 20. Crawford KHD, Eguia R, Dingens AS, Loes AN, Malone KD, Wolf CR, Chu HY, Tortorici MA,
566 Veessler D, Murphy M, Pettie D, King NP, Balazs AB, Bloom JD. 2020. Protocol and Reagents
567 for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization
568 Assays. *Viruses* 12.

- 569 21. Mattiuzzo G, Bentley EM, Hassall M, Routley S, Bernasconi V, Kristiansen P, Harvala H,
570 Roberts D, Semple G, Turtle LC, Openshaw PJ, Baillie K, Investigators C, Nissen-Meyer LSH,
571 Brants AB, Atkinson E, Rigsby P, Padley D, Almond N, Rose NJ, Page M. Establishment of the
572 WHO International Standard and Reference Panel for anti-SARS-CoV-2 antibody 60.
- 573 22. Bedford T, Greninger AL, Roychoudhury P, Starita LM, Famulare M, Huang M-L, Nalla A,
574 Pepper G, Reinhardt A, Xie H, Shrestha L, Nguyen TN, Adler A, Brandstetter E, Cho S, Giroux
575 D, Han PD, Fay K, Frazar CD, Ilcisin M, Lacombe K, Lee J, Kiavand A, Richardson M, Sibley TR,
576 Truong M, Wolf CR, Nickerson DA, Rieder MJ, Englund JA, Seattle Flu Study Investigators,
577 Hadfield J, Hodcroft EB, Huddleston J, Moncla LH, Müller NF, Neher RA, Deng X, Gu W,
578 Federman S, Chiu C, Duchin JS, Gautom R, Melly G, Hiatt B, Dykema P, Lindquist S, Queen K,
579 Tao Y, Uehara A, Tong S, MacCannell D, Armstrong GL, Baird GS, Chu HY, Shendure J,
580 Jerome KR. 2020. Cryptic transmission of SARS-CoV-2 in Washington state. *Science*
581 370:571–575.
- 582 13. AdviseDx SARS-CoV-2 IgGII, Manufacturer’s Insert.
583 <https://www.fda.gov/media/146371/download>. Accessed March 10th, 2020.
- 584 24. Lynch KL, Whitman JD, Lacanienta NP, Beckerdite EW, Kastner SA, Shy BR, Goldgof GM,
585 Levine AG, Bapat SP, Stramer SL, Esensten JH, Hightower AW, Bern C, Wu AHB. 2021.
586 Magnitude and Kinetics of Anti–Severe Acute Respiratory Syndrome Coronavirus 2
587 Antibody Responses and Their Relationship to Disease Severity. *Clin Infect Dis* 72:301–308.



- 588 25. Padoan A, Bonfante F, Pagliari M, Bortolami A, Negrini D, Zuin S, Bozzato D, Cosma C,
589 Sciacovelli L, Plebani M. 2020. Analytical and clinical performances of five immunoassays for
590 the detection of SARS-CoV-2 antibodies in comparison with neutralization activity.
591 EBioMedicine 62:103101.
- 592 26. Prince HE, Givens TS, Lapé-Nixon M, Clarke NJ, Schwab DA, Batterman HJ, Jones RS, Meyer
593 WA, Kapoor H, Rowland CM, Haji-Sheikhi F, Marlowe EM. 2020. Detection of SARS-CoV-2
594 IgG Targeting Nucleocapsid or Spike Protein by Four High-Throughput Immunoassays
595 Authorized for Emergency Use. J Clin Microbiol 58:e01742-20, /jcm/58/11/JCM.01742-
596 20.atom.
- 597 27. Theel ES, Haring J, Hilgart H, Granger D. 2020. Performance Characteristics of Four High-
598 Throughput Immunoassays for Detection of IgG Antibodies against SARS-CoV-2. J Clin
599 Microbiol 58.
- 600 28. Manalac J, Yee J, Calayag K, Nguyen L, Patel PM, Zhou D, Shi R-Z. 2020. Evaluation of Abbott
601 anti-SARS-CoV-2 CMIA IgG and Euroimmun ELISA IgG/IgA assays in a clinical lab. Clin Chim
602 Acta 510:687–690.
- 603 29. Boonyaratanakornkit J, Morishima C, Selke S, Zamora D, McGuffin S, Shapiro AE, Campbell
604 VL, McClurkan CL, Jing L, Gross R, Liang J, Postnikova E, Mazur S, Lukin VV, Chaudhary A, Das
605 MK, Fink SL, Bryan A, Greninger AL, Jerome KR, Holbrook MR, Gernsheimer TB, Wener MH,
606 Wald A, Koelle DM. 2021. Clinical, laboratory, and temporal predictors of neutralizing

- 607 antibodies against SARS-CoV-2 among COVID-19 convalescent plasma donor candidates. J
608 Clin Invest 131.
- 609 30. Das MK, Chaudhary A, Bryan A, Wener MH, Fink SL, Morishima C. 2020. Rapid Screening
610 Evaluation of SARS-CoV-2 IgG Assays Using Z-Scores to Standardize Results. Emerg Infect Dis
611 26:2501–2503.
- 612 31. Perera RA, Mok CK, Tsang OT, Lv H, Ko RL, Wu NC, Yuan M, Leung WS, Chan JM, Chik TS,
613 Choi CY, Leung K, Chan KH, Chan KC, Li K-C, Wu JT, Wilson IA, Monto AS, Poon LL, Peiris M.
614 2020. Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
615 March 2020. Eurosurveillance 25:2000421.
- 616 32. Schmidt F, Weisblum Y, Muecksch F, Hoffmann H-H, Michailidis E, Lorenzi JCC, Mendoza P,
617 Rutkowska M, Bednarski E, Gaebler C, Agudelo M, Cho A, Wang Z, Gazumyan A, Cipolla M,
618 Caskey M, Robbiani DF, Nussenzweig MC, Rice CM, Hatzioannou T, Bieniasz PD. 2020.
619 Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric
620 viruses. J Exp Med 217.
- 621 33. cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit Version 4.0.
- 622 34. Boyarsky BJ, Werbel WA, Avery RK, Tobian AAR, Massie AB, Segev DL, Garonzik-Wang JM.
623 2021. Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid
624 Organ Transplant Recipients. JAMA <https://doi.org/10.1001/jama.2021.4385>.

- 625 35. Bryan A, Fink SL, Gattuso MA, Pepper G, Chaudhary A, Wener MH, Morishima C, Jerome KR,
626 Mathias PC, Greninger AL. 2020. SARS-CoV-2 Viral Load on Admission Is Associated With 30-
627 Day Mortality. *Open Forum Infect Dis* 7:ofaa535.
- 628 36. Jack AD, Hall AJ, Maine N, Mendy M, Whittle HC. 1999. What Level of Hepatitis B Antibody
629 Is Protective? *J Infect Dis* 179:489–492.
- 630 37. Zhang W, Davis BD, Chen SS, Sincuir Martinez JM, Plummer JT, Vail E. 2021. Emergence of a
631 Novel SARS-CoV-2 Variant in Southern California. *JAMA* 325:1324.
- 632 38. Deng X, Garcia-Knight MA, Khalid MM, Servellita V, Wang C, Morris MK, Sotomayor-
633 González A, Glasner DR, Reyes KR, Gliwa AS, Reddy NP, Martin CSS, Federman S, Cheng J,
634 Balcersek J, Taylor J, Streithorst JA, Miller S, Kumar GR, Sreekumar B, Chen P-Y, Schulze-
635 Gahmen U, Taha TY, Hayashi J, Simoneau CR, McMahon S, Lidsky PV, Xiao Y, Hemarajata P,
636 Green NM, Espinosa A, Kath C, Haw M, Bell J, Hacker JK, Hanson C, Wadford DA, Anaya C,
637 Ferguson D, Lareau LF, Frankino PA, Shivram H, Wyman SK, Ott M, Andino R, Chiu CY. 2021.
638 Transmission, infectivity, and antibody neutralization of an emerging SARS-CoV-2 variant in
639 California carrying a L452R spike protein mutation. *medRxiv* 2021.03.07.21252647.
- 640 39. McCallum M, Bassi J, Marco AD, Chen A, Walls AC, Iulio JD, Tortorici MA, Navarro M-J,
641 Silacci-Fregni C, Saliba C, Agostini M, Pinto D, Culap K, Bianchi S, Jaconi S, Cameroni E,
642 Bowen JE, Tilles SW, Pizzuto MS, Guastalla SB, Bona G, Pellanda AF, Garzoni C, Voorhis
643 WCV, Rosen LE, Snell G, Telenti A, Virgin HW, Piccoli L, Corti D, Veessler D. 2021. SARS-CoV-2
644 immune evasion by variant B.1.427/B.1.429. *bioRxiv* 2021.03.31.437925.


645

646



649 **Figure 1** AdviseDx SARS-CoV-2 IgG II values for patients with a PCR-confirmed SARS-CoV-2
650 infection who were >14 days post symptom onset or >10 days following first positive PCR result
651 and control sera collection prior to the SARS-CoV-2 pandemic (A). The dotted line represents

652 the assay positive cutoff (50 AU/mL) set by the manufacturer. Gold squares indicate patients
653 who seroconverted at 13 and 18 days following their first positive PCR result. Purple triangle
654 represents a severely ill COVID-19 patient who died 17 days post-symptom onset. 104 serum
655 samples obtained prior to the emergence of SARS-CoV-2 were analyzed for assay specificity (B).
656 The median value of these negative controls was 1.8 AU/mL (range: 0-32.9). The dotted line
657 represents the positive threshold.
658



659

660 **Figure 2** Correlation of AdviseDx SARS-CoV-2 IgG II assays results to the Abbott Architect anti-N

661 (A), EuroImmun anti-S (B), Roche anti-S (C), and GenScript (D) assays. The same specimens were


662 run on all five platforms. AdviseDx results were log-transformed before performing linear

663 regression. Results demonstrated strong agreement and goodness of fit (R^2) was measured as


664 0.42, 0.84, 0.73, and 0.74, respectively. Dotted lines represent the manufacturer's positive

665 cutoff value for each assay.

666



667



668

669 **Figure 3** Serial measurements of anti-S IgG levels and surrogate neutralization results in four
670 patients with acute SARS-CoV-2 infection (A) and four patients who received the mRNA-1273 or

671 BNT162b2 SARS-CoV-2 vaccine (B). Increasing anti-S levels and neutralization were observed in
672 all patients as time from exposure increased. At later time points, vaccinated patients had
673 lower anti-S levels with sustained neutralization activity. Curves plotted in Prism 9 using akima
674 spline.
675

A

	Abbott SARS-CoV-2 IgG (anti-N) +	Abbott SARS-CoV-2 IgG (anti-N) -
AdviseDx +	54	0
AdviseDx -	0	3

676 PPA: 100% (93.4 to 100%)

B

	Eurolmmun +	Eurolmmun -
AdviseDx +	44	2
AdviseDx -	0	3

677 PPA: 100% (92.0 to 100%)

C

	Roche anti-S +	Roche anti-S -
AdviseDx +	46	0
AdviseDx -	0	3

678 PPA: 100% (92.3 to 100%)

D

	GenScript +	GenScript -
AdviseDx +	89	9
AdviseDx -	0	4

679 PPA: 100% (95% CI: 95.9-100%)

680

681 **Table 1** Excellent categorical agreement is observed between the AdviseDx SARS-CoV-2 IgG II
682 assays and Abbott SARS-CoV-2 IgG (A), Eurolmmun (B), and Roche Elecsys Anti-SARS-CoV-2 S (C)
683 enzyme immunoassays. Positive percent agreement was calculated for samples from patients
684 that were greater than 14 days from symptom onset or 10 days post first positive PCR result.
685 Positive percent agreement of the AdviseDx SARS-CoV-2 IgG II assays to the GenScript surrogate
686 virus neutralization was 100% when all samples with GenScript data were measured
687 irrespective of collection time (D). In discrepant cases (AdviseDx+/ GenScript-) the AdviseDx
688 result ranged from 50.1-290.7 AU/mL, above the assay positive threshold of 50 AU/mL.

IU/mL	Abbott Architect anti-N (index)		AdviseDx anti-S (AU/mL)		GenScript (% neutralization)		Roche (AU/mL)		EuroImmun (OD ratio)	
	mean (%CV)	categorical	mean (%CV)	categorical	mean (%CV)	categorical	mean (%CV)	categorical	mean (%CV)	categorical
100	2.5 (1.2%)	POS	618.9 (0.9%)	POS	48.3 (3.4%)	POS	88.2 (1.0%)	POS	2.30 (2.5%)	POS
50	1.27 (1.2%)	NEG	301.6 (0.6%)	POS	36.6 (13.6%)	POS	40.3 (0.1%)	POS	1.29 (3.1%)	POS
10	0.2 (0%)	NEG	59.5 (4.6%)	POS	3.9 (78.5%)	NEG	6.2 (0.1%)	POS	0.46 (14.6%)	NEG
5	0.09 (0%)	NEG	29.9 (1.0%)	NEG	3.5 (108%)	NEG	2.4 (0.03%)	POS	0.2 (22.9%)	NEG
1	0.01 (43%)	NEG	6.1 (5.7)	NEG	0.4 (1032.8%)	NEG	0.4 (0%)	NEG	0.08 (12.5%)	NEG

689

690 **Table 2** Comparison of WHO International Standard results across multiple platforms demonstrates varying levels of sensitivity. The
 691 positive cutoff for the Abbott Architect anti-N, AdviseDx, Roche, and EuroImmun assays were calculated as 56.2 IU/mL, 8.4 IU/mL,
 692 3.2 IU/mL, and 30.2 IU/mL, respectively. Each sample was analyzed in triplicate. Positive cutoff: Abbott Architect anti-N (1.4),
 693 AdviseDx (50 AU/mL), GenScript (30%), Roche (0.8 AU/mL), EuroImmun (0.8).

694

695

	Abbott AdviseDx (anti-S)			Roche Elecsys (anti-S)			Euroimmun (anti-S)		
	Median (AU/mL)	10th Percentile	90th Percentile	Median (AU/mL)	10th Percentile	90th Percentile	Median (index)	10th Percentile	90th Percentile
Week 1 (n=35)	2.2	0.7	4.7	0.4	0.4	0.4	0.2	0.1	0.3
Week 2 (n=22)	5.2	1.4	448.3	1.8	0.4	147.8	0.3	0.2	4.2
Week 3 (n=24)	794.3	303.2	3823.9	40.8	8.9	227.0	4.4	2.8	9.1
Week 4 (n=22)	2109.9	508.8	23958.1	>250	18.1	>250	7.0	4.4	9.7
Week 5 (n=16)	21962.1	6283.7	>25000	>250	75.8	>250	9.5	5.8	10.5
Week 6 (n=13)	16919.1	5200.7	>25000	>250	>250	>250	10.5	9.3	11.7
Week 7 (n=8)	23881.4	7304.4	>25000	>250	>250	>250	10.6	10.0	11.4
Week 8 (n=3)	14648.2	7439.6	22929.6	>250	>250	>250	9.8	8.9	10.4
Week 9 (n=8)	8747.2	4049.9	>25000	>250	>250	>250	9.4	7.8	11.4
Week 10-11 (n=4)	21770.3	15256.8	>25000	>250	>250	>250	11.6	11.2	12.4

696

697 **Table 3** Longitudinal antibody response in a group of healthy volunteers following vaccination with mRNA-1273 or BNT162b2 SARS-
698 CoV-2 as measured by three different anti-S assays. Initial detectable positive values were identified at Week 3 with values peaking
699 at Week 7, consistent with anamnestic booster response. Values are reported as the median antibody levels along with the 10-90th
700 percentile

701

702

	AdviseDx		EuroImmun		Roche		Abbott Architect Anti-N	GenScript	Pseudovirus Neutralization	Pseudovirus Neutralization	Strain
	AU/mL	IU/mL	OD ratio	IU/mL	AU/mL	IU/mL	Index Value	% neut.	µg/ml	ND50	
Fisheries 1	5303.2	858.0	6.87	306.4	N/A	N/A	6.93	89.2	N/A	N/A	N/A
Fisheries 2	1240.4	200.9	3.86	169.4	70.16	81.0	4.07	83.6	N/A	N/A	N/A
Fisheries 3	N/A	N/A	N/A	N/A	N/A	N/A	4.72	93.1	N/A	N/A	N/A
HCW_1	1639.2	265.4	7	312.3	>250	>282.6	0.01	89.6	0.005311	188	20C/B.1.429
HCW_2	1058.5	171.5	5.2	230.4	>250	>282.6	0.04	35.6	0.006564	152	20C/B.1.429
HCW_3	7099.5	1148.6	9.5	426.0	>250	>282.6	0.06	96.5	0.001729	577	20C/B.1.429
HCW_4	3266.7	528.7	9.7	435.1	>250	>282.6	0.01	89.9	0.002727	366	20C/B.1.427
HCW_5	10856.7	1756.2	10.5	471.5	>250	>282.6	0.02	97.5	0.001282	788	20C/B.1.429

703

704

705 **Table 4** Comparison of SARS-CoV-2 IgG results among three individuals with demonstrated resistance to multiple SARS-CoV-2

706 challenges and five individuals >6 weeks following vaccination who subsequently developed SARS-CoV-2 infection. Both individuals

707 with resistance to multiple infectious challenge (Fisheries) and vaccine-breakthrough individuals (HCW) demonstrated similar levels

708 of anti-S titers and activity. In only one of five vaccine-breakthrough cases were AdviseDx levels and GenScript neutralization values

709 lower than fishing vessel individuals. International units per milliliter (IU/mL) were calculated for the AdviseDx, Euroimmune, and

710 Roche assays. As expected, Abbott anti-nucleocapsid IgG levels were negative among vaccinated health care workers because they
711 were tested prior to seroconversion to their breakthrough infection, indicating the anti-S levels measured are due to vaccination.

